- Home
- AVR vs BNY Comparison
AVR vs BNY Comparison
Compare AVR & BNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVR
- BNY
- Stock Information
- Founded
- AVR 1999
- BNY 2001
- Country
- AVR Australia
- BNY United States
- Employees
- AVR N/A
- BNY N/A
- Industry
- AVR
- BNY Trusts Except Educational Religious and Charitable
- Sector
- AVR
- BNY Finance
- Exchange
- AVR NYSE
- BNY Nasdaq
- Market Cap
- AVR 241.5M
- BNY 249.4M
- IPO Year
- AVR 2024
- BNY N/A
- Fundamental
- Price
- AVR $3.40
- BNY $10.19
- Analyst Decision
- AVR Strong Buy
- BNY
- Analyst Count
- AVR 4
- BNY 0
- Target Price
- AVR $16.50
- BNY N/A
- AVG Volume (30 Days)
- AVR 293.1K
- BNY 52.7K
- Earning Date
- AVR 05-16-2025
- BNY 01-01-0001
- Dividend Yield
- AVR N/A
- BNY 3.93%
- EPS Growth
- AVR N/A
- BNY N/A
- EPS
- AVR N/A
- BNY N/A
- Revenue
- AVR $2,703,000.00
- BNY N/A
- Revenue This Year
- AVR $37.33
- BNY N/A
- Revenue Next Year
- AVR $141.49
- BNY N/A
- P/E Ratio
- AVR N/A
- BNY N/A
- Revenue Growth
- AVR N/A
- BNY N/A
- 52 Week Low
- AVR $3.27
- BNY $8.60
- 52 Week High
- AVR $8.79
- BNY $10.80
- Technical
- Relative Strength Index (RSI)
- AVR N/A
- BNY 41.04
- Support Level
- AVR N/A
- BNY $10.11
- Resistance Level
- AVR N/A
- BNY $10.39
- Average True Range (ATR)
- AVR 0.00
- BNY 0.10
- MACD
- AVR 0.00
- BNY -0.01
- Stochastic Oscillator
- AVR 0.00
- BNY 41.18
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr has an investment objective to provide current income exempt from regular U.S. federal income tax and New York State and New York City personal income taxes. The Trust seeks to achieve its investment objective by investing primarily in municipal bonds exempt from U.S. federal income taxes and New York State and New York City personal income taxes.